Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALVOEYE-HD study of AVT29 versus Eylea HD in diabetic macular edema
2025-522231-34-00Phase 3Authorised
- Sponsor
- Alvotech
- Start
- Mar 2026
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 9
01
Overview
Phase 3, randomised, double-blind trial in diabetic macular edema (DME) comparing AVT29 with Eylea HD (2 arms). Primary endpoint: Change from baseline in best-corrected visual acuity. Planned start Mar 2026; status: authorised.
02
Drugs
avt29aflibercept
03
Conditions
diabetic macular edema (DME)
Beyond the preview
Go deeper on 2025-522231-34-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-522231-34-00.